• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Chen H, Hu Y, Fan Y, Wu G, Cang S, Yang Y, Yang N, Ma R, Jing G, Liu A, Xu X, Tang S, Cheng Y, Yu Y, Wu YL. 22P Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00276-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
2
Liu SY, Tu HY, Wei XW, Yan HH, Dong X, Cui J, Zhou Z, Xu C, Zheng M, Li Y, Wang Z, Du Y, Chen Y, Ma R, Wang B, Cang S, Yang JJ, Chen H, Zhou Q, Wu YL. 385P Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
3
Wu YL, Zhao J, Hu J, Wu J, Xu Y, Yang Z, Liu Z, Jiang L, Chen J, Yu Y, Huang M, Dong X, Liu L, Feng W, Wu L, Cang S, Sun J, Xie Q, Chen HJ. 388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
4
Lu S, Jian H, Zhang Y, Song Z, Zhao Y, Wang P, Jiang L, Gong Y, Zhou J, Dong X, Yang N, Fang J, Zhuang W, Cang S, Ma R, Shi J, Wu P, Lu J, Xiang Z, Shi Z, Zhang L, Wang Y. OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
5
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Chen C, Jin X, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S. EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
6
Ji W, Li X, Cang S, Xiang Y, Li X, Zhang J, Tan J, Wang Q, Jiang D, Zhang H, Lu S. 1129P Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
7
Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Stefaniak V, Lin Y, Wang S, Zhang W, Sun L, Zhang Y. 4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]  Open
8
Cheng Y, Wang J, Cang S, Cao L, Chen E, Dong X, Fan Y, Gao B, Guo Q, Huang D, Li S, Liu A, Lv D, Pan Y, Tang K, Yao W, Ye F, Yu Y, Zang A, Gao M. 60TiP ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC). J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01902-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
9
Yang Z, Tian Y, Cang S, Zhang L, Liu L. The synthesis of a series of fluorescent emitters and their application for dye lasing and cation sensing. Spectrochim Acta A Mol Biomol Spectrosc 2021;246:118978. [PMID: 33038857 DOI: 10.1016/j.saa.2020.118978] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 09/16/2020] [Accepted: 09/17/2020] [Indexed: 05/13/2023]
10
Zhang L, Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Xu W, Ji Y, Peng B. ID:1329 ORIENT-11: Sintilimab + Pemetrexed + Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC. J Thorac Oncol 2020. [DOI: 10.1016/j.jtho.2020.08.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
11
Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M, Ren X, Zhou J, Li B, Zhou H, Wang S, Xu W, Peng B, Zhang L. LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]  Open
12
Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, Zhou J, Zhou C, Li B, Li J, Fan M, Zhang W, Yang W, Wang S, Zhou H. LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2289] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
13
Cang S, Lu Q, Ma Y, Liu D. Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways. Curr Cancer Drug Targets 2010;10:539-45. [DOI: 10.2174/156800910791517217] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2009] [Accepted: 04/04/2010] [Indexed: 11/22/2022]
14
Cang S, Lu Q, Ma Y, Liu D. Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways. Curr Cancer Drug Targets 2010. [DOI: 10.2174/1568210203845840096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
15
Cang S, Ohta S, Chiba H, Johdo O, Nomura H, Nagamatsu Y, Yoshimoto A. New Naphthyridinomycin-type Antibiotics, Aclidinomycins A and B, from Streptomyces halstedi. J Antibiot (Tokyo) 2001;54:304-7. [PMID: 11372787 DOI: 10.7164/antibiotics.54.304] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
16
Lu Q, Yao S, Huang C, Lan Y, Cang S, Qiao Y, Wang R. [A cohort study on the relationship between vegetable intake and risks of lung cancer in the Tin Corporation (YTC) miners in Yunnan]. Zhonghua Liu Xing Bing Xue Za Zhi 2000;21:205-7. [PMID: 11860786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
17
Cang S. Nursing organisation, Part 3. Power to the sisters. Health Soc Serv J 1983;93:538-9. [PMID: 10261656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
18
Cang S. Nursing organisation, Part 2. Tangled web of responsibility. Health Soc Serv J 1983;93:502-3. [PMID: 10261653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
19
Cang S. Nursing organisation, Part 1. When the organisation needs a check-up. Health Soc Serv J 1983;93:466-7. [PMID: 10261647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
20
Cang S. Nursing organisation and the question of 'counselling'. Nurs Times 1983;79:37-8. [PMID: 6550291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
21
Cang S. The work of the health services organisation research unit, Brunel University. Program Notes Assoc Univ Programs Health Adm 1981;97:1-13. [PMID: 10254304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
22
Cang S. Nursing research: problems of aim, method and content. J Adv Nurs 1979;4:453-8. [PMID: 256949 DOI: 10.1111/j.1365-2648.1979.tb00878.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
23
Cang S, Clarke F. Home care of the sick--an emerging general analysis based on schemes in France. Community Health (Bristol) 1978;9:167-72. [PMID: 204445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
24
Cang S. An alternative to hospital. Lancet 1977;1:742-3. [PMID: 66531 DOI: 10.1016/s0140-6736(77)92180-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA